RU2006133260A - Соединения замещенного пиразолина, их получение и применение в качестве лекарственных средств - Google Patents

Соединения замещенного пиразолина, их получение и применение в качестве лекарственных средств Download PDF

Info

Publication number
RU2006133260A
RU2006133260A RU2006133260/04A RU2006133260A RU2006133260A RU 2006133260 A RU2006133260 A RU 2006133260A RU 2006133260/04 A RU2006133260/04 A RU 2006133260/04A RU 2006133260 A RU2006133260 A RU 2006133260A RU 2006133260 A RU2006133260 A RU 2006133260A
Authority
RU
Russia
Prior art keywords
optionally
straight
hydrogen
branched chain
independently
Prior art date
Application number
RU2006133260/04A
Other languages
English (en)
Russian (ru)
Inventor
Роса КУБЕРЕС-АЛЬТИСЕН (ES)
Роса КУБЕРЕС-АЛЬТИСЕН
Бонифасио ГУТЬЕРРЕС-СИЛЬВА (ES)
Бонифасио ГУТЬЕРРЕС-СИЛЬВА
Хорди ФРИГОЛА-КОНСТАНСА (ES)
Хорди ФРИГОЛА-КОНСТАНСА
Original Assignee
Лабораториос Дель Др. Эстеве С.А. (Es)
Лабораториос Дель Др. Эстеве С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04021974A external-priority patent/EP1637522A1/de
Application filed by Лабораториос Дель Др. Эстеве С.А. (Es), Лабораториос Дель Др. Эстеве С.А. filed Critical Лабораториос Дель Др. Эстеве С.А. (Es)
Publication of RU2006133260A publication Critical patent/RU2006133260A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
RU2006133260/04A 2004-02-17 2005-02-14 Соединения замещенного пиразолина, их получение и применение в качестве лекарственных средств RU2006133260A (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ES200400378 2004-02-17
ES200400378 2004-02-17
US80453404A 2004-03-19 2004-03-19
US10/804,534 2004-03-19
EP04021974.3 2004-09-16
EP04021974A EP1637522A1 (de) 2004-09-16 2004-09-16 Substituierte Pyrazoline zur Senkung von Triglyceriden im Blut

Publications (1)

Publication Number Publication Date
RU2006133260A true RU2006133260A (ru) 2008-04-10

Family

ID=34864786

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006133260/04A RU2006133260A (ru) 2004-02-17 2005-02-14 Соединения замещенного пиразолина, их получение и применение в качестве лекарственных средств

Country Status (10)

Country Link
EP (1) EP1718619A1 (de)
JP (1) JP2007522252A (de)
KR (1) KR20060135815A (de)
AU (1) AU2005212817A1 (de)
BR (1) BRPI0507790A (de)
CA (1) CA2556568A1 (de)
IL (1) IL177454A0 (de)
NO (1) NO20064186L (de)
RU (1) RU2006133260A (de)
WO (1) WO2005077909A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510647A (ja) 2003-10-30 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体調節剤としてのアラルキルアミン類
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009704A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
ES2330993B1 (es) * 2005-07-15 2010-07-06 Laboratorios Del Dr. Esteve, S.A. Combinacion de antagonista del receptor de cannabinoides de tipo pirazolina y estatina.
EP1746090A1 (de) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Substituierte Pyrazoline mit vorbestimmter Stereochemie zur Senkung von Triglyceriden im Blut
WO2007009683A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
EP1749527A1 (de) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Verwendung substituierter Pyrazolinderivate zur Behandlung des metabolischen Syndroms
EP1743637A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Verwendung substituierter Pyrazolinderivate und Kombinationen davon zur Behandlung des metabolischen Syndroms
WO2007009700A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
ES2336883B1 (es) * 2005-07-15 2011-03-22 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre.
WO2007009707A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
EP1743889A1 (de) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituierte Pyrazoline mit vorbestimmter Stereochemie zur Senkung von Triglyceriden im Blut
EP1749526A1 (de) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Verwendung substituierter Pyrazolinderivate zur Behandlung von Nahrungsmittel bedingten Störungen, wie Obesitas oder des metabolischen Syndroms in Patienten mit fortgeschrittener Diabetis
WO2007009701A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
EP1745781A1 (de) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Kombination von Cannabinoid Rezeptor Antagonist des Pyrazolin-Typs und Statin
WO2007009706A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1743639A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Verwendung substituierter Pyrazolinderivate zur Behandlung von Krankheiten im Zusammenhang mit Blutgerinnung
EP1944296A1 (de) * 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Amorphe Phase eines substituierten Pyrazolins, seine Herstellung und Verwendung als Medikament
EP1944295A1 (de) * 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Nicht racemische Verbindungen von (R)-N-piperidinyl-5-(4-chlorophenyl)1-1(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid und (S)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid
EP1946779A1 (de) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Zusammensetzung enthaltend substituierte Pyrazoline und gegen Dyslipämie wirksame Mittel
EP2114892A1 (de) * 2007-01-17 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituierte pyrazolinverbindungen mit acat-hemmungsaktivität sowie deren herstellung und medizinische verwendung
US20100099712A1 (en) * 2007-01-17 2010-04-22 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds with acat inhibition activity
EP1950203A1 (de) * 2007-01-24 2008-07-30 Laboratorios del Dr. Esteve S.A. Substitutierte Pyrazolinverbindungen mit ACAT, ihre Herstellung und Verwendung als Medikamente
EP1947088A1 (de) * 2007-01-17 2008-07-23 Laboratorios del Dr. Esteve S.A. Substitutierte Pyrazolinverbindungen, ihre Herstellung und Verwendung als Medikamente
KR101395658B1 (ko) 2012-09-20 2014-05-16 서울대학교산학협력단 4-(5-(2-메톡시페닐)-3-(ｐ-톨릴)-4,5-디하이드로-1Ｈ-피라졸-1-일)-4-옥소부탄산을 포함하는 골대사성 질환의 예방 및 치료용 조성물
KR101466377B1 (ko) * 2012-10-22 2014-12-01 건국대학교 산학협력단 디메톡시페닐디히드로피라졸릴나프탈레놀 유도체 및 그 제법 및 항암제로서의 용도
US9604964B2 (en) * 2012-11-16 2017-03-28 Bristol-Myers Squibb Company Dihydropyrazole GPR40 modulators
CN104812748B (zh) * 2012-11-16 2017-10-24 百时美施贵宝公司 二氢吡唑gpr40调节剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1053661B (it) * 1966-09-27 1981-10-10 Farmacosmici S P A Ammidi dell acido 3 5 metil 5 3 pirazol carbossilico
ATE57690T1 (de) * 1987-01-05 1990-11-15 Du Pont Pyrazolin mit insektizidischer aktivitaet.
ES2174757B1 (es) * 2001-04-06 2003-11-01 Esteve Labor Dr Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.

Also Published As

Publication number Publication date
WO2005077909A1 (en) 2005-08-25
NO20064186L (no) 2006-11-14
IL177454A0 (en) 2006-12-10
KR20060135815A (ko) 2006-12-29
BRPI0507790A (pt) 2007-07-17
JP2007522252A (ja) 2007-08-09
CA2556568A1 (en) 2005-08-25
AU2005212817A1 (en) 2005-08-25
EP1718619A1 (de) 2006-11-08

Similar Documents

Publication Publication Date Title
RU2006133260A (ru) Соединения замещенного пиразолина, их получение и применение в качестве лекарственных средств
RU2006133262A (ru) Соединения замещенного пиразолина, их получение и применение в качестве лекарственных средств
WO2000056728A1 (en) Tetrahydropyran derivatives and their use as therapeutic agents
CN107098871B (zh) 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
CN1104428C (zh) 用作法呢基－蛋白转移酶抑制剂的取代的苯并芳庚并吡啶
EA006583B1 (ru) Производные азетидина, способ их получения и содержащие их фармацевтические композиции
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
RU2008105761A (ru) 4-5-дигидро-1н-пиразольные производные, их получение и применение в качестве лекарственного средства
WO2007129111A1 (en) Diazepine derivatives as 5-ht2a antagonists
JP2003529595A (ja) ５−ｈｔ受容体リガンドとしてのフェニルスルホニルピペラジニル誘導体
JP2002525280A (ja) ５−ｈｔ２レセプター活性を有するインダゾール誘導体
CN107098876B (zh) 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
CN106795124A (zh) 取代的1H‑吡唑并[3,4‑d]嘧啶类化合物的合成
CN1167698C (zh) 用作神经激肽受体拮抗剂的n-三唑基甲基哌嗪衍生物
CN117062819A (zh) 多环化合物及其用途
JP5460614B2 (ja) アゼチジン誘導体、それらの調製、およびそれらの治療における適用
EP1921072A1 (de) 1,2,3-Triazolderivate als Cannabinoid-Rezeptor Modulatoren
AU2004262970B2 (en) Treatment for Alzheimer's disease and related conditions
WO1998047887A1 (fr) Nouveaux derives d'epoxysuccinamide et sels associes
CN111902403A (zh) 作为抗癌剂的取代的亚炔基化合物
WO2002014277A1 (fr) Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci
CA2498285C (en) Aroyl-piperidine derivatives
EP1637522A1 (de) Substituierte Pyrazoline zur Senkung von Triglyceriden im Blut
JP2011530576A (ja) アゼチジン多置換化合物、これらの調製、およびこれらの治療的適用
JP2023505046A (ja) スフィンゴシン－１－リン酸受容体アゴニスト、その製造方法、およびそれを活性成分として含有する医薬組成物

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090619

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090619